AstraZeneca diabetes drug approved by European Commission

  • Fri 15 Nov 2019 07:42

    AstraZeneca said its drug to improve glucose levels in adults with type-2 diabetes had been approved by the European Commission.

    The approval was based on data from five phase III trials evaluating combinations of Forxiga (dapagliflozin) and Onglyza (saxagliptin) on a background of metformin in patients with inadequately controlled type-2 diabetes.

    Across the trials, the combination of Forxiga, Onglyza and metformin was superior at reducing average blood glucose levels compared to Forxiga with metformin, Onglyza with metformin, or glimepiride with metformin, the company said.

<< Back <<

AstraZeneca (AZN)

7,258.00p +29.00p (+0.40%) delayed 18:29PM
Price delayed by 15 minutes.